Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

semaglutide

Details

Files
Generic Name:
semaglutide
Project Status:
Active
Therapeutic Area:
Weight management
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
Wegovy
Project Line:
Reimbursement Review
Project Number:
SR0841-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of equal to or greater than 27 kg/m2 and established cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease).
Submission Type:
Resubmission
Fee Schedule:
Schedule A
Indications:
Wegovy (semaglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obesity), or• 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open17-Oct-24
Call for patient/clinician input closed06-Dec-24
Submission received27-Nov-24
Submission accepted11-Dec-24
Review initiated12-Dec-24
Draft CADTH review report(s) provided to sponsor for comment06-Mar-25
Deadline for sponsors comments18-Mar-25
CADTH review report(s) and responses to comments provided to sponsor09-Apr-25
Expert committee meeting (initial)23-Apr-25
Draft recommendation issued to sponsorMay 05, 2025
To
May 07, 2025
Draft recommendation posted for stakeholder feedback15-May-25
End of feedback period30-May-25

Files

Patient and Clinician Group input View PDF
Last Updated : March 6, 2025